Futura Medical plc announced that it has been granted allowance of its EU patent which will provide protection for MED3000 until 2040 in all European markets. In all other key ED markets including the US, the Company is continuing to prosecute patent applications to provide wider patent protection and further options for patent filings to extend scope of protection is also progressing.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.45 GBX | +0.14% | -0.56% | +39.02% |
Apr. 10 | Futura Medical hails results as erectile dysfunction drug drives sales | AN |
Apr. 10 | Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+39.02% | 133M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FUM Stock
- News Futura Medical plc
- Futura Medical plc Announces European Patent Office Grants Patent for Med3000